Comprehensive comparison of three commercial human whole-exome capture platforms.

ABSTRACT:

Background

Exome sequencing, which allows the global analysis of protein coding sequences in the human genome, has become an effective and affordable approach to detecting causative genetic mutations in diseases. Currently, there are several commercial human exome capture platforms; however, the relative performances of these have not been characterized sufficiently to know which is best for a particular study.

Results

We comprehensively compared three platforms: NimbleGen's Sequence Capture Array and SeqCap EZ, and Agilent's SureSelect. We assessed their performance in a variety of ways, including number of genes covered and capture efficacy. Differences that may impact on the choice of platform were that Agilent SureSelect covered approximately 1,100 more genes, while Nimb

SUBMITTER: Asan 

PROVIDER: S-EPMC3308058 | biostudies-literature | 2011 Sep

REPOSITORIES: biostudies-literature